Trends in inpatient antiparkinson drug use in the USA, 2001–2012 by James A. G. Crispo et al.
PHARMACOEPIDEMIOLOGYAND PRESCRIPTION
Trends in inpatient antiparkinson drug use in the USA, 2001–2012
James A. G. Crispo1,2 & Yannick Fortin1 & Dylan P. Thibault3 & Matthew Emons4 &
Lise M. Bjerre5,6,7 & Dafna E. Kohen7 & Santiago Perez-Lloret8 & Donald Mattison1,9 &
Allison W. Willis3 & Daniel Krewski1
Received: 2 April 2015 /Accepted: 1 June 2015 /Published online: 18 June 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract
Purpose Although therapeutic options and clinical guide-
lines for Parkinson’s disease (PD) have changed significant-
ly in the past 15 years, prescribing trends in the USA
remain unknown. The purpose of this population-based co-
hort study was to examine patterns of inpatient
antiparkinson drug use between January 2001 and Decem-
ber 2012 in relation to clinical guideline publication, drug
introduction/withdrawal, and emerging safety concerns.
Methods A total of 16,785 inpatients receiving pharmaco-
logical treatment for PD were identified in the Cerner
Health Facts database. Our primary outcome was standard-
ized (age, sex, race, and census region) annual prevalence
of antiparkinson drug use. We also examined antiparkinson
medication trends and polypharmacy by age and sex.
Results The most frequently prescribed antiparkinson
drugs between 2001 and 2012 were levodopa (85 %)
and dopamine agonists (28 %). Dopamine agonist use
began declining in 2007, from 34 to 27 % in 2012. The
decline followed publication of the American Academy
of Neurology’s practice parameter refuting levodopa
toxicity, pergolide withdrawal, and pramipexole label
revisions. Despite safety concerns for cognitive impair-
ment and falls, individuals ≥80 years of age demonstrat-
ed stable rates of dopamine agonist use from 2001 to
2012. Polypharmacy was most common in younger
patients.
Conclusions Dopamine agonist use declined from 2007 to
2012, suggesting that increased awareness of safety issues
and practice guidelines influenced prescribing. These
events appear to have minimally influenced treatment pro-
vided to older PD patients. Antiparkinson prescribing
trends indicate that safety and best practice information
may be communicated effectively.
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Introduction
Treatment options for both early and advanced Parkinson’s dis-
ease (PD) have expanded considerably over the last 15 years.
The introduction of dopamine agonists (DAs) to treat PD in the
late 1990s, USA Food and Drug Administration approval of
deep brain stimulation for PD in 2002, and approval of other
antiparkinson drugs such as entacapone and rasagiline reflect the
substantial public and private investment in improving the lives
of those affected by PD. Increasing knowledge of antiparkinson
drug safety (including reports of DA-associated impulse control
disorders [1, 2] and cardiotoxicity [3–9]) and efficacy, findings
that PD progression is not accelerated by levodopa [10, 11], and
the failures of selegiline and rasagiline to demonstrate neuropro-
tection [11, 12] have the potential to influence clinical practice.
Ideally, prescribing practices reflect known risks and bene-
fits, which can change over time. Evidence-based clinical guide-
lines are routinely published and updated by professional orga-
nizations such as the International Parkinson and Movement
Disorder Society and the American Academy of Neurology
(AAN) to reflect changes in scientific knowledge [11, 13–15].
Additionally, treatment availability and adverse drug event
reporting may also contribute to changing antiparkinson drug
prescribing practices over time. Previous USA PD drug utiliza-
tion studies have consistently demonstrated sociodemographic
disparities in PD treatment [16–18]; however, prescribing trends
are unreported. Furthermore, the impact of evidence-based
guideline publication, drug availability, and safety concerns on
antiparkinson drug prescribing has been investigated in Europe,
Asia, and Australia [19–22], but not in the USA. Previous stud-
ies have shown that levodopa is the most commonly prescribed
antiparkinson drug [19–22], that prescribing of DAs may be
influenced by safety concerns [20], and that despite safety con-
cerns, DAs may be routinely prescribed to older adults [22].
Nevertheless, changes in antiparkinson drug use in relation to
practice guideline publication, drug availability, and emerging
safety concerns remain unknown in the USA.
To address this knowledge gap, we performed a 12-year ret-
rospective analysis of electronic medical records (EMRs) from
more than 16,000 individuals with PD in Cerner Health Facts®,
an EMR database comprised of complete encounter data for
patients who received care at any USA health center subscribed
to Cerner EMR services. The primary objective of our study was
to describe patterns of antiparkinson drug use between January
2001 and December 2012 in relation to clinical guideline publi-
cation, drug introduction/withdrawal, and emerging safety con-
cerns. PD prevalence increases sharply with age [23], and yet
older adults are also most vulnerable to side effects from PD
medications [2, 6, 24]. Our secondary objectives were therefore
to examine temporal trends and relative differences in the phar-
macological management of PD by age and sex.
Materials and methods
This study was approved by the Health Sciences and Science
Research Ethics Board at the University of Ottawa, Ottawa,
ON, Canada.
Data source
Study data were derived from the Cerner Corporation’s (Kan-
sas City, Missouri) Health Facts® data warehouse. Launched
in January 2000, Health Facts® is an electronic medical record
system that stores time-stamped patient records, including
sociodemographic, geographical, clinical, laboratory, pharma-
cy, and billing data for clients. As of 2014, there were over 300
contributing subscribers to the Health Facts®, and data from
more than 230 million patient encounters, representing over
41 million distinct patients. Health Facts® subscribers are sit-
uated in all USA census regions: Northeast (40 %), Midwest
(27 %), South (21 %), and West (11 %). The majority of
subscribers are academic medical centers, which contribute
approximately 65 % of all encounters. Health Facts® is well
suited for studying responses to changing practice guidelines,
specifically among inpatients, since pharmacy data are most
complete for inpatient populations.
Study population
We searched all encounters from January 1, 2000, to Decem-
ber 31, 2012, to identify individuals with a primary or second-
ary diagnosis of PD according to the International Classifica-
tion of Diseases, Ninth Revision (ICD-9; code 332 for PD, or
code 332.0 for Paralysis Agitans). Information from all en-
counters within the study period was extracted for individuals
with one or more PD diagnoses (n=40,609). We excluded
individuals diagnosed at any time with a primary or secondary
diagnosis of secondary parkinsonism (ICD-9, code 332.1) or
other degenerative diseases of the basal ganglia (ICD-9, code
333.0) (n=1,450, 3.6 %). In effort to exclude individuals with
atypical PD and cases of PDmisclassification, we also exclud-
ed those who were diagnosed with PD prior to age 40 (n=375,
0.96 %) and those without a recorded age at time of PD diag-
nosis (n=18, 0.05 %). Because all outpatient physicians do
not use Health Facts®, we further restricted the cohort to inpa-
tients who were prescribed one or more antiparkinson drugs
between January 1, 2001, and December 31, 2012 (n=17,375,
45 %). Finally, to accommodate direct standardization, we
restricted the cohort to individuals with complete demograph-
ic information (age, sex, and race) recorded (n=16,785,
97 %).
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Demographic data and care setting characteristics
Demographic data collected from encounters included patient
age, sex (male or female), and race (Caucasian, African Amer-
ican, Asian, Hispanic, or other). Patient age at time of first
recorded PD diagnosis, defined as the study-qualifying en-
counter, was categorized into the following age strata: 40–
64, 65–79, and 80+years. The principal diagnosis for each
study encounter was identified and classified according to
commonly used ICD-9 categories. Care setting characteristics
collected from study-qualifying encounters included location
type (urban or rural), teaching status (teaching or nonteach-
ing), and census region (Northeast, South, Midwest, or West).
Drug utilization
Our primary outcome was standardized (age, sex, race, and
census region) annual prevalence of antiparkinson drug use
among inpatients with PD who were prescribed one or more
antiparkinson drugs. Antiparkinson drugs were identified by
searching hospital formularies for generic names of interest
and classified according to the following categories: (1) levodo-
pa, (2) DA (ergot (bromocriptine, cabergoline, and pergolide)
and nonergot (pramipexole, ropinirole, and rotigotine)), (3)
monoamine oxidase-B (MAO-B) inhibitor (selegiline and
rasagiline), (4) catechol-o-methyltransferase (COMT) inhibitor
(tolcapone and entacapone), (5) amantadine, and (6) anticholin-
ergic (benztropine, biper iden, procycl idine, and
trihexyphenidyl). After excluding drug orders that were can-
celled or not dispensed, the number of inpatients with an
antiparkinson prescriptionwas calculated annually by drug class
from January 1, 2001, to December 31, 2012. Using data from
the 2005 American Community Survey (USA Census Bureau),
we calculated annual standardized (age, sex, race, and census
region) antiparkinson drug use to examine prescribing trends
over time. Subgroup analyses contrasted prescribing trends by
age and sex. We defined PD drug complexity as the sum of
unique drug classes prescribed to an individual patient in one
calendar year, categorized as 1, 2, 3, and 4+ drugs.
Factors affecting prescribing practice
Our a priori hypothesis was that the greatest changes in the most
commonly prescribed drug classes—levodopa and DAs—
would be temporally related to (1) practice guideline publica-
tion, (2) official safety concerns (such as market withdrawal),
and (3) the 2008 pramipexole (Mirapex) label revisions warning
of the risk of impulse control issues (urges to gamble and in-
creased sexual urges). To test this hypothesis, we examined the
change in levodopa and DA use between the event year and 1,
2, and 3 years after (1) publication of the April 2006 AAN
practice parameter reporting that levodopa does not accelerate
PD progression and that no pharmacological intervention is
neuroprotective, (2) the voluntary withdrawal of pergolide (an
ergot-derived DA) from the market in 2007 due to concerns
about cardiotoxicity, and (3) the December 2008 pramipexole
label revisions which added precautions about uncontrollable
urges to the label. We used a Wilcoxon-Mann-Whitney test to
examine whether standardized annual prevalence of levodopa
and DA use significantly changed after events of interest. In
order to ensure independence of the data between the
two years being compared, individuals appearing in both years
(6–25 % of sample depending on the particular comparison)
were excluded from the analyses. Two-tailed p values less than
0.0015 were considered statistically significant.
Results
Demographics and care setting characteristics
We identified 16,785 individuals with PD from the Cerner
Health Facts® data warehouse who satisfied our inclusion/
exclusion criteria between January 1, 2001, and December
31, 2012 (Table 1). The demographic characteristics of our
Table 1 Demographics of inpatients with PD and care setting
characteristics
Population


























a Age at first recorded diagnosis in Health Facts
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population were similar to previously published epidemio-
logical studies of PD in the USA [23, 25]. Caucasians com-
prised 91.2 % of the population; the remaining individuals
were African-American (6.1 %), Asian (0.7 %), Hispanic
(1.0 %), and other races (1.0 %). Men (54.9 %) were more
prevalent than women (45.1 %) (Table 1). The majority
(88.4 %) of individuals were aged 65 years or older at the
time of their first recorded PD diagnosis in Health Facts®,
which agrees with published data on age-stratified PD prev-
alence [23, 25]. Care centers were most likely located in
urban areas (99.6 %), academic medical centers (64.9 %),
and in the Northeast USA (49.2 %). Supplementary Table 1
shows that study cohort demographics and care setting cen-
sus regions were similar across study years. Supplementary
Table 2 demonstrates that individuals within our study co-
hort were primarily admitted to hospital for diseases of the
circulatory system, diseases of the respiratory systems, and
symptoms, signs, and ill-defined conditions, which is con-
sistent with reasons for inpatient admission among older
USA adults [26].
Changes in drug utilization in relation to AAN practice
guidelines
As shown in Fig. 1 and Table 2, use of levodopa was stable
prior to and after the 2006 publication of the AAN’s evidence-
based review of neuroprotective strategies and alternative
therapies in PD, which put forth that there was no advantage
to initiating therapy with levodopa alternatives. DAs were the
most commonly used levodopa alternatives at that time,
and DA utilization steadily increased from 21.7 % (2001)
to 31.2 % (2006) during the same pre-guideline period. Use
of nonergot DAs was significantly higher (+3.2 %;
p<0.0015) in the year immediately following release of
the AAN practice guideline; however, did not further in-
crease in subsequent years (Table 2). Prevalent use of ergot
DAs agonists significantly declined 2 (−0.6 %; p<0.0015)
and 3 years (−0.8 %; p<0.0015) after AAN practice guide-
line publication (Table 2).
Changes in drug utilization in relation to pergolide
withdrawal
In March 2007, pergolide (an ergot DA) was withdrawn from
the USA market over mounting evidence of cardiotoxicity,
specifically valvular disease [27]. Use of DAs (mainly
nonergot DAs) surged prior to the withdrawal of pergolide,
increasing from 21.7 % in 2001 to a maximum of 34.3 % in
2007 (Fig. 1). At the time of withdrawal, approximately 1.5 %
of inpatients receiving pharmacotherapy for PD were treated
with ergot DAs. Levodopa use was not impacted by the with-
drawal of pergolide (Table 2). Similarly, the withdrawal of one
of its class members had little immediate impact on DA use;
however, DA (−5.5 %; p<0.0015) and nonergot DA (−4.9 %;
p<0.0015) use significantly declined 3 years following
pergolide’s withdrawal (Table 2).
Fig. 1 Standardized prevalence
of antiparkinson drug use over
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Changes in drug utilization in relation to pramipexole
label revisions
In-depth precautions about uncontrollable urges were added to
the pramipexole (Mirapex) label in 2008 [28]. Moreover,
2008 was a focal year in the use trend of DAs, as it was the
first year in our sample where DA use decreased (−1.6 %;
p>0.0015) from the previous year (Fig. 1 and Table 2). A
significant decrease (−5.5 %; p<0.0015) in the use of
nonergot DAs was observed 3 years following the
pramipexole label revisions, while use of levodopa remained
unchanged (Table 2).
Prescribing trends by age and sex
No discernable differences according to age or sex were ob-
served in the use trends of levodopa or DAs following (1)
publication of the 2006 AAN practice parameter, (2) the
2007 withdrawal of pergolide from the USA market, and (3)
the 2008 pramipexole labeling revisions (Fig. 2).We observed
differences in levodopa (Fig. 2a) and DA (Fig. 2c) use within
older adult PD populations (80+years of age). On average,
73.4 % of adults aged 40–64 years used levodopa, which rose
to 90.1 % for individuals aged 80+years. Younger patients
(40–64 years of age) were uncommon and were more likely
to be prescribed DAs, which decreased with increasing age
(Fig. 2c). Adults aged 65–79 years had intermediate rates of
DA and levodopa use, with levodopa favored over DAs. As
shown in Fig. 2, year-to-year trends in levodopa and DA use
were more volatile for younger patients, while the pharma-
cological management of PD proved to be more resistant to
change among older patients. Despite emerging safety con-
cerns pertaining to the use of DAs in older populations, use
of DAs did not decrease over time in the oldest (80+years
of age) population, 20.2 % of who were prescribed a DA.
Polypharmacy (two or more PD drugs) was most common
in patients 40–64 years of age (42.2 %) and decreased with
increasing age (38.6 and 25.5 % among patients 65–79 and
80+years of age, respectively). Annual prevalence of levo-
dopa (Fig. 2b) and DA (Fig. 2d) use was similar among
men and women.
Discussion
While unpublished data may regularly be used by the phar-
maceutical industry to inform marketing decisions, there are
significant benefits to publicly reporting such information.
Prescribing patterns serve as markers of practice parameter
adherence and response to new scientific evidence. Real-
world prescription studies may also identify deviations from
standard practice in the form of age, sex, race, or socioeco-
nomic treatment disparities. Our retrospective analyses of in-
patients with PD who received pharmacological treatment be-
tween January 1, 2001, and December 31, 2012 are, to our
knowledge, the first national analysis of trends in PD medica-
tion use in the USA. Our primary finding is that there has been
a shift in prescribing practices for PD in the USA and that
Table 2 Change in levodopa and dopamine agonist utilization in relation to guideline publication, pergolide withdrawal, and emerging safety concerns
Event Event year (%a) Year after (%a) % Change* 2 years after (%a) % Change* 3 years after (%a) % Change*
AAN practice recommendations (2006)
Levodopa 85.1 86.5 +1.4 83.3 −1.8 83.3 −1.8
Dopamine agonists 31.2 34.4 +3.2 34.0 +2.8 32.4 +1.2
Ergot 1.3 1.5 +0.2 0.7 −0.6* 0.5 −0.8*
Nonergot 30.0 33.2 +3.2* 33.4 +3.4 31.9 +1.9
Pergolide withdrawal (2007)
Levodopa 86.5 83.3 −3.2 83.3 −3.2 82.9 −3.6
Dopamine agonists 34.4 34.0 −0.4 32.4 −2.0 28.9 −5.5*
Ergot 1.5 0.7 −0.8 0.5 −1.0 0.6 −0.9
Nonergot 33.2 33.4 +0.2 31.9 −1.3 28.3 −4.9*
Pramipexole label revisions (2008)
Levodopa 83.3 83.3 0.0 82.9 −0.4 85.1 +1.8
Dopamine agonists 34.0 32.4 −1.6 28.9 −5.1 28.5 −5.5*
Ergot 0.7 0.5 −0.2 0.6 −0.1 0.5 −0.2
Nonergot 33.4 31.9 −1.5 28.3 −5.1 27.9 −5.5*
Due to polypharmacy, the sum of the standardized annual prevalent use for antiparkinson drugs studied may exceed 100 % in a given year
AAN American Academy of Neurology
a Standardized annual prevalent use expressed as a percentage
*Significant at p=0.0015≈0.05/36, using a Bonferroni adjustment to control for the 36 individual tests conducted
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these changes are due in part to emerging safety concerns and
evidence of efficacy. Secondary analyses revealed that (1)
despite safety concerns, older PD patients were persistently
prescribed DAs, (2) use of levodopa and DAs did not greatly
differ between men and women over time, and (3)
antiparkinson drug polypharmacy was most common in youn-
ger PD patients.
DAs gained popularity as the initial pharmacotherapy for
PD in the early 2000’s because of concerns over levodopa
neurotoxicity and that motor fluctuations in PD were due to
levodopa treatment duration [29, 30]. Published in April 2006,
the world’s largest professional association of neurologists,
the AAN, completed an evidence-based review of the thera-
pies purported to delay the onset of motor fluctuations or
decrease motor progression in PD [11]. The expert review
reported that levodopa did not accelerate PD progression
and that no pharmacological intervention was neuroprotec-
tive. Our findings show that USA prescribing trends of
antiparkinson drugs, notably DAs, did not immediately
change as a result of the AAN’s practice parameter publica-
tion. There are several possible reasons for this finding. Con-
tinued disagreement regarding the toxicity of levodopa likely
contributed to the observed delay in response. The notion that
DAs are less toxic (rather than simply less potent) continues to
have a strong footing in the scientific literature and lay press
[31, 32]. Notwithstanding any disagreement, recent evidence
reaffirms the AAN’s finding that levodopa is not toxic [10,
33–35]. Lack of prescriber awareness is another possible rea-
son as to why there was little immediate response to the prac-
tice parameter. There is currently no mandate for specialty
Fig. 2 Standardized prevalence of antiparkinson drug use over time by
age and sex. Levodopa use over time by age (a) and sex (b), and
dopamine agonist use over time by age (c) and sex (d). AAN American
Academy of Neurology, DA dopamine agonist. Trends were not
standardized by the stratification variable for analyses of annual
prevalence of antiparkinson drug use by age and sex
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care for PD, as exists for equally complicated conditions such
as cancer. The majority of individuals diagnosed with PD do
not have neurologist care, especially in the years immediately
following diagnosis [36, 37]. Primary care physician continu-
ing medical education (CME) training may not include spe-
cialty practice parameter updates in a timely fashion. Whether
lack of awareness of paradigm shifts in PD treatments is as-
sociated with worse outcomes will need to be considered in
future studies. Finally, despite knowledge of the latest guide-
lines, sound clinical judgment may have dictated that
switching some patients from a DA to levodopa was contra-
indicated, particularly in patients responding well to a DA or
those who had previously experienced intolerable side effects
with levodopa.
We next examined inpatient antiparkinson drug use in rela-
tion to increasing concerns of adverse events such as cardiovas-
cular complications and impulse control disorders (ICDs). Stud-
ies have demonstrated that DAs, specifically ergot derivatives,
are associated with the development of cardiac fibrosis and val-
vular heart disease [3, 6, 8, 9]. Although the majority of DAs
prescribed within our study period were nonergot derivatives, it
is possible that decreasing use of DAs reflects emerging con-
cerns of cardiac safety with all DAs. Recent reports of increased
risk of heart failure with nonergot DAs suggest that researchers
are beginning to examine this phenomenon carefully, hopefully
providing guidelines that better enable informed use of DAs in
patients with cardiovascular disease [4–7]. In addition to cardio-
vascular concerns, reports of DA-associated ICDs have surged
in the last decade [1, 2, 38]. ICDs are characterized by problems
in self-control despite personal repercussions and may include
pathological gambling, compulsive buying, hypersexuality,
binge eating, and punding [1, 2]. While there is currently no
black box warning of ICDs with DAs, the precautions section
of the pramipexole (Mirapex) label was revised in December
2008 to include information about uncontrollable urges while
taking pramipexole, including intense urges to gamble, in-
creased sexual urges, and other intense urges [28]. Increasing
knowledge of these risks by clinicians may have contributed in
part to the reduced use of DAs after 2007.
Although most physicians avoid DAs in adults >60 years
of age over concerns of cognitive impairment [39, 40], a large
proportion of individuals >65 years of age in our dataset were
prescribed DAs. There was also little change in levodopa or
DA use in the most elderly patients. These data may reflect
differences in care structure for the oldest PD patients, who
are more likely to reside in nursing homes and are least
likely to utilize specialty care [41]. Alternatively, older pa-
tients or the physicians who care for them may be more
averse to the risks of known levodopa-induced side effects
(nausea, hallucinations, dyskinesias, and orthostatic hypoten-
sion) and instead rely on DAs and other therapies for symp-
tomatic PD. It is also possible that older PD patient popula-
tions have a lower susceptibility to ICDs or have more social
support to prevent personal and financial consequences of
mild dopamine-associated impulsivity, reducing the need to
change medications. However, differences in care quality
must be considered, as studies have found that older PD
patients are undertreated on examination and have
undertreatment-related disability [42, 43].
Our study has a number of strengths. Data for this study
were derived from a large number of patients spanning multi-
ple treatment centers over 10+years, with relatively complete
pharmacy data. While other studies have investigated
antiparkinson drug use cross-sectionally [22, 44], within a
single center [16] or within smaller patient populations [20,
22, 44], our study offers broader insight on the influence of
practice parameter publication, drug introduction/withdrawal,
and increasing knowledge of drug efficacy and safety on pre-
scribing patterns. Since the majority of our study data are
derived from urban teaching centers, they are assumed to be
highly sensitive to detecting modifications to clinical practice,
including changing prescribing patterns in response to new
guidelines or evidence.
There are a number of limitations to our study. Due to
lacking outpatient drug information, our study was restricted
to inpatients prescribed one or more antiparkinson drugs dur-
ing the study period. This was done to minimize false nega-
tives for antiparkinson treatment. However, because PD is
rarely the principal reason for hospital admission [45, 46],
we could not account for radical changes in PD regimen that
accompanied an admission. Moreover, since differences may
exist in the identification and treatment of PD among inpa-
tients and individuals receiving care at academic centers; our
findings may not reflect antiparkinson prescribing trends in
the general USA PD patient population. Nevertheless, our
reported trends provide valuable information on antiparkinson
drug use by the oldest and sickest individuals with PDwho are
hospitalized, many of who (those <65 years of age) are not
represented in other large national databases such as Medi-
care. We could not account for PD disease severity and did
not take comorbidities and the use of other medications into
account, which may impact prescribing at the individual level.
However, our study examined all PD cases over time (rather
than a fixed cohort), reducing the potential impact of individ-
ual disease progression, comorbidities, and use of other drugs
on our results. Unmeasured factors, including drug pricing
and pharmaceutical company promotional activity, have cer-
tainly influenced antiparkinson drug utilization over time.
Therefore, our observed trends in antiparkinson drug use
may only be explained in part by examined events. Finally,
there are also limitations to our statistical approach. Calculated
p values from the Wilcoxon-Mann-Whitney test may over-
state the significance of changes in drug utilization over time
in the presence of clustering in the data, such as might occur if
there were a tendency for differences in prescribing practices
among hospitals. Percent changes in Table 2, which represent
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changes in levodopa and DA use for the entire population
under study, could mask differential changes by population
subgroup; however, trends by age, sex, race, and census re-
gion shown in Supplementary Table 1 did not generally show
marked differences among these subgroups.
Despite study limitations, we demonstrate that changes in
the use of antiparkinson drugs in the USA have occurred over
time and that these changes may reflect increasing knowledge
of drug safety and efficacy. Future studies that examine the
impact of care structure and quality on prescribing practices,
particularly with regard to barriers to the dissemination, ac-
ceptance, and adoption clinical guidelines, as well as studies
which investigate outcomes associated with drug choice in
select PD populations are needed.
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